Shawn Moaddeb is an entrepreneur with over 25 years’ experience in the medical device industry. Former VP of RF Technology at Vessix Vascular, Shawn is a named inventor on over 100 issued and pending patents in the areas of RF catheter-based renal denervation, percutaneous mitral valve catheter-based therapy, electrophysiology and cardiac ablation systems, medical laser systems, GI, and implantable pacemaker and defibrillator devices.

Shawn is a results-driven senior executive with over 25 years’ experience. He is an entrepreneur with a strong background in both start-up and large established organizations, including Johnson & Johnson and St. Jude Medical, and has achieved several successful exits. Formerly VP of RF Technology at Vessix Vascular (sold to Boston Scientific in 2012 for $425M), developing novel radiofrequency balloon catheter technology for a variety of clinical applications, Shawn is a co-founder and currently serves as President & CEO of Lavita Technologies, a venture-backed medical device incubator company creating unique therapies that address unmet clinical needs. He is also an Entrepreneur-In-Residence with Hobart Group, a leading company specializing in investment in and the active management of medical device portfolio companies, where he has responsibility for identifying and evaluating investment opportunities. Shawn is a board member and co-founder of several medical device companies, including Savona Therapeutics (early cancer detection), Lavita Technologies (neuromodulation therapy for autoimmune inflammatory diseases), Micardia Corp (percutaneous mitral valve treatment), Ellipse Technologies (devices for the treatment of skeletal deformities, recently sold to NuVasive for $380M), and Oncogenics Guidance Systems (cancer therapies). He is named inventor on over 100 issued and pending patents.